ASH 2022 | FUSION-AML-001: molecular changes associated with azacitidine & durvalumab in TP53m AML and HR-MDS
Jan Philipp Bewersdorf, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, discusses the molecular changes associated with treatment with azacitidine and durvalumab in patients with newly diagnosed TP53-mutated acute myeloid leukemia (AML) or higher-risk myelodysplastic syndromes (HR-MDS) from the FUSION-AML-001 trial (NCT02775903). The study did not show an overall survival (OS) benefit for this combination, and while there were epigenetic changes associated with the upregulation of immune checkpoints, they did not correlate with clinically relevant endpoints either. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
